Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising th...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-07804-8 |
| id |
doaj-ead11814b4ee465d85398bdcb2064c81 |
|---|---|
| record_format |
Article |
| spelling |
doaj-ead11814b4ee465d85398bdcb2064c812021-05-11T09:59:44ZengNature Publishing GroupNature Communications2041-17232018-12-01911910.1038/s41467-018-07804-8Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcerNicole Scherr0Raphael Bieri1Sangeeta S. Thomas2Aurélie Chauffour3Nitin Pal Kalia4Paul Schneide5Marie-Thérèse Ruf6Araceli Lamelas7Malathy S. S. Manimekalai8Gerhard Grüber9Norihisa Ishii10Koichi Suzuki11Marcel Tanner12Garrett C. Moraski13Marvin J. Miller14Matthias Witschel15Vincent Jarlier16Gerd Pluschke17Kevin Pethe18Swiss Tropical and Public Health InstituteSwiss Tropical and Public Health InstituteLee Kong Chian School of Medicine, Nanyang Technological UniversityCR7, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), Sorbonne Universités, UPMC Université Paris 06Lee Kong Chian School of Medicine, Nanyang Technological UniversityBASF SESwiss Tropical and Public Health InstituteSwiss Tropical and Public Health InstituteSchool of Biological Sciences, Nanyang Technological UniversitySchool of Biological Sciences, Nanyang Technological UniversityDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious DiseasesDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious DiseasesSwiss Tropical and Public Health InstituteDepartment of Chemistry and Biochemistry, Montana State UniversityDepartment of Chemistry and Biochemistry, University of Notre DameBASF SECR7, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), Sorbonne Universités, UPMC Université Paris 06Swiss Tropical and Public Health InstituteLee Kong Chian School of Medicine, Nanyang Technological UniversityMycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising therapeutic candidate for BU.https://doi.org/10.1038/s41467-018-07804-8 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Nicole Scherr Raphael Bieri Sangeeta S. Thomas Aurélie Chauffour Nitin Pal Kalia Paul Schneide Marie-Thérèse Ruf Araceli Lamelas Malathy S. S. Manimekalai Gerhard Grüber Norihisa Ishii Koichi Suzuki Marcel Tanner Garrett C. Moraski Marvin J. Miller Matthias Witschel Vincent Jarlier Gerd Pluschke Kevin Pethe |
| spellingShingle |
Nicole Scherr Raphael Bieri Sangeeta S. Thomas Aurélie Chauffour Nitin Pal Kalia Paul Schneide Marie-Thérèse Ruf Araceli Lamelas Malathy S. S. Manimekalai Gerhard Grüber Norihisa Ishii Koichi Suzuki Marcel Tanner Garrett C. Moraski Marvin J. Miller Matthias Witschel Vincent Jarlier Gerd Pluschke Kevin Pethe Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer Nature Communications |
| author_facet |
Nicole Scherr Raphael Bieri Sangeeta S. Thomas Aurélie Chauffour Nitin Pal Kalia Paul Schneide Marie-Thérèse Ruf Araceli Lamelas Malathy S. S. Manimekalai Gerhard Grüber Norihisa Ishii Koichi Suzuki Marcel Tanner Garrett C. Moraski Marvin J. Miller Matthias Witschel Vincent Jarlier Gerd Pluschke Kevin Pethe |
| author_sort |
Nicole Scherr |
| title |
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer |
| title_short |
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer |
| title_full |
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer |
| title_fullStr |
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer |
| title_full_unstemmed |
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer |
| title_sort |
targeting the mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of buruli ulcer |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-12-01 |
| description |
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising therapeutic candidate for BU. |
| url |
https://doi.org/10.1038/s41467-018-07804-8 |
| work_keys_str_mv |
AT nicolescherr targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT raphaelbieri targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT sangeetasthomas targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT aureliechauffour targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT nitinpalkalia targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT paulschneide targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT mariethereseruf targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT aracelilamelas targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT malathyssmanimekalai targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT gerhardgruber targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT norihisaishii targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT koichisuzuki targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT marceltanner targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT garrettcmoraski targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT marvinjmiller targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT matthiaswitschel targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT vincentjarlier targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT gerdpluschke targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer AT kevinpethe targetingthemycobacteriumulceranscytochromebc1aa3forthetreatmentofburuliulcer |
| _version_ |
1721448890545209344 |